Paydirt
AR
Insider

Andrew Reardon

CLO & Secretary

Andrew Reardon (CLO & Secretary) filed 7 Form 4 reports in the trailing twelve months (0 purchases, 7 sales), most often in Ligand Pharmaceuticals Incorporated (LGND). The largest single filing was $1.5M of LGND (4,796 sh across 6 lots, as filed), executed Jul 1.

Add to watchlist
Return, ttmiAverage return per filing, trailing twelve months
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
returns measure stock purchases only
Filings, ttm
7
0 buys · 7 sells
Median delay
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$7.7M
shares × price, as filed
Last traded
Sep 3
Filed Sep 8

Median ADV $104.4M across their filed names

Open performance
Volume by month
$1.5M$751K$0Oct 2024Apr 2025Oct 2025Apr 2026Jun 2025 · sells $104KMar 2026 · sells $666KApr 2026 · sells $846KMay 2026 · sells $1.0MJun 2026 · sells $999KJul 2026 · sells $1.5MAug 2026 · sells $1.3MSep 2026 · sells $1.3M
Buys $0 Sells $7.8M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on
Healthcare 7 filings

Sector per market data · by filing · past 12 months

Most traded names
LGND Ligand Pharmaceuticals Incorporated LGND · 0 buys · 9 sells 9 filings
Recent filings
LGNDSALE Ligand Pharmaceuticals Incorporated View filing → $199K
2,000 sh × $99.60
Exec Sep 23 2024
Filed Sep 25 2024 · 5:30 PM ET